Article
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Dec 2020
Lin J J, Liu S V, McCoach C E, Zhu V W, Tan A C, Yoda S, Peterson J, Do A, Prutisto-Chang K, Dagogo-Jack I, Sequist L V, Wirth L J, Lennerz J K, Hata A N, Mino-Kenudson M, Nardi V, Ou S-H I, Tan D S-W, Gainor J F
Abstract excerpt
BACKGROUND: Rearranged during transfection (RET) gene fusions are a validated target in non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this indication. Insights into...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.